AR019669A1 - Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen. - Google Patents
Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen.Info
- Publication number
- AR019669A1 AR019669A1 ARP990102861A ARP990102861A AR019669A1 AR 019669 A1 AR019669 A1 AR 019669A1 AR P990102861 A ARP990102861 A AR P990102861A AR P990102861 A ARP990102861 A AR P990102861A AR 019669 A1 AR019669 A1 AR 019669A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- aryl
- hydrogen atom
- preparation
- alkyl
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 108050001286 Somatostatin Receptor Proteins 0.000 title abstract 4
- 102000011096 Somatostatin receptor Human genes 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 230000001575 pathological effect Effects 0.000 title abstract 3
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000005157 Somatostatin Human genes 0.000 abstract 1
- 108010056088 Somatostatin Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- JEVCWSUVFOYBFI-UHFFFAOYSA-N cyanyl Chemical compound N#[C] JEVCWSUVFOYBFI-UHFFFAOYSA-N 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 150000004908 diazepines Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 abstract 1
- 229960000553 somatostatin Drugs 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Uso para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales está involucrado por lo menos uno de losreceptores de somatostatina, de diazepinas de formula general (1) en el cual W representa el átomode hidrogeno o un radical de formula R-X-C(Y), R representaun radical arilo o heteroarilo, estando los radicales arilo y heteroarilo sustituidos optativamente; X representa un radical de formula -(CH2)n-Z en el cual Zrepresenta un enlace covalente,NH, O o S y n es un entero de 0 y 2; Y representa O o S, R1 representa uno o más grupos idénticos o diferentes, elegidos entre:un átomo de hidrogeno, hidroxi, un radical halo, un radical alquilo inferior y alcoxi inferior; R2a y R2b representan, independientemente, un átomo dehidrogeno; un radical alquilo inferior, alquenilo inferior o alquinilo inferior, estando los radicales alquilo, alquenilo y alquinilo optativamente sustituidoso un radical R21Z21- en el cual Z21 representa O, C(O), OC(O), S, R21 representa un átomo de hidrogeno, un radical alquilo, arilo o arilalquilo inferior; R3representa un átomo de hidrogeno, un radical halo, nitro o ciano, un radical alquilo con 1 a 10 átomos de carbono, radicales alquenilo inferior, alquiniloinferior, cicloalquilo, cicloalquilalquilo, arilo, arilalquilo, ariloxialquilo inferior, heteroarilo o heteroarilalquilo, estando los radicales alquilo,alquenilo, alquilo, cicloalquilo, arilo y heteroarilo optativamente sustituidos; o un radical R31Z31-en el cual Z31 representa O, C(O), OC(O), S, y R31representa un átomo de hidrogeno, un radical alquilo inferior, arilo o arilalquilo inferior , o una sal de este producto, para la preparacion de un medicamentopara tratar estados patologicos o enfermedades en las cuales están involucrados uno (o más) receptores de somatostatina. Dado que los desordenes patologicosasociados con la somatostatina son numerosos, resulto importante hallar compuesto que tengan afinidad con receptores de somatostatina.Como nuevos compuestoscomprendidos por la formula (1), se encuentran los de la formula general (2) en la cual W representa el átomo de hidrogeno o un radical de formula
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9807509A FR2779652B1 (fr) | 1998-06-15 | 1998-06-15 | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR019669A1 true AR019669A1 (es) | 2002-03-13 |
Family
ID=9527389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990102861A AR019669A1 (es) | 1998-06-15 | 1999-06-15 | Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7015213B1 (es) |
| EP (1) | EP1087978A1 (es) |
| JP (1) | JP2002518400A (es) |
| KR (1) | KR20010052836A (es) |
| CN (1) | CN100348600C (es) |
| AR (1) | AR019669A1 (es) |
| AU (1) | AU758206B2 (es) |
| CA (1) | CA2335724A1 (es) |
| FR (1) | FR2779652B1 (es) |
| HK (1) | HK1039780A1 (es) |
| HU (1) | HUP0102300A3 (es) |
| IL (1) | IL139954A0 (es) |
| MY (1) | MY118652A (es) |
| NO (1) | NO20006352L (es) |
| NZ (1) | NZ509313A (es) |
| PL (1) | PL344831A1 (es) |
| RU (1) | RU2229299C2 (es) |
| TW (1) | TW513434B (es) |
| WO (1) | WO1999065917A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6987105B2 (en) * | 2000-04-28 | 2006-01-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of thienotriazolodiazepines |
| WO2002057241A1 (en) * | 2000-12-22 | 2002-07-25 | Bayer Pharmaceuticals Corporation | 8-(AMINOALKOXYMINO)-8H-DIBENZO[a,e]TRIAZOLO[4,5-c]CYCLOHEPTENES AS GROWTH HORMONE SECRETAGOGUES |
| JP5478262B2 (ja) * | 2007-12-28 | 2014-04-23 | 田辺三菱製薬株式会社 | 抗癌剤 |
| CA2799420C (en) | 2010-05-14 | 2018-10-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
| US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| JP2016531113A (ja) | 2013-07-25 | 2016-10-06 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 転写因子の阻害剤およびその使用 |
| MX379463B (es) | 2013-11-08 | 2025-03-10 | Dana Farber Cancer Inst Inc | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| MX2016009974A (es) | 2014-01-31 | 2016-10-31 | Dana Farber Cancer Inst Inc | Derivados de diaminopirimidina bencensulfona y sus usos. |
| RU2722179C2 (ru) * | 2014-02-28 | 2020-05-28 | Тэнша Терапеутикс, Инк. | Лечение состояний, ассоциированных с гиперинсулинемией |
| ES2725928T3 (es) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida |
| EP3177626A4 (en) | 2014-08-08 | 2017-12-27 | Dana Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| KR20170032474A (ko) | 2014-08-08 | 2017-03-22 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| BR112017008714A2 (pt) | 2014-10-27 | 2017-12-19 | Tensha Therapeutics Inc | inibidores de bromodomínio |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| KR20180049058A (ko) | 2015-09-11 | 2018-05-10 | 다나-파버 캔서 인스티튜트 인크. | 시아노 티에노트리아졸로디아제핀 및 그의 용도 |
| CA2996977A1 (en) | 2015-09-11 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
| SG10201913450PA (en) | 2015-11-25 | 2020-03-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
| AR112788A1 (es) * | 2017-09-07 | 2019-12-11 | Eisai R&D Man Co Ltd | Compuesto pentacíclico |
| IL285511B2 (en) | 2019-03-05 | 2024-10-01 | Eisai R&D Man Co Ltd | Pentacyclic heterocyclic compounds and pharmaceutical compositions comprising them for the treatment of cognitive dysfunction |
| TWI849070B (zh) | 2019-03-05 | 2024-07-21 | 日商衛材R&D企管股份有限公司 | 五環化合物之鹽及其等之結晶 |
| CN111533745A (zh) * | 2020-05-20 | 2020-08-14 | 成都药明康德新药开发有限公司 | 叔丁基-3-(氨基甲基)二氢-5h-三唑并二氮杂卓-8(9h)-甲酸基酯制法 |
| IL302769A (en) | 2020-11-16 | 2023-07-01 | Boehringer Ingelheim Int | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists |
| JP2025501761A (ja) | 2021-12-22 | 2025-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血小板活性化因子受容体アンタゴニストとしてのシクロペンタチオフェンカルボキサミド誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95708C (fi) * | 1988-10-31 | 1996-03-11 | Eisai Co Ltd | Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi |
| GB8907257D0 (en) * | 1989-03-31 | 1989-05-17 | Rech Et D Applic Scient Scras | New derivatives of hetrazepine as anti-paf and anti-ischemic agents |
| GB8907256D0 (en) * | 1989-03-31 | 1989-05-17 | Rech Et D Applic Scient Scras | New derivatives of hetrazepine as anti-asthmatic anti-allergic and gastro-intestinal protectors |
| GB8911030D0 (en) * | 1989-05-13 | 1989-06-28 | Scras | Hetrazepine derivatives |
| OA09202A (fr) * | 1990-04-02 | 1992-06-30 | Sod Conseils Rech Applic | Procédé de préparation des nouveaux dérivés de la thiéno-triazolo-diazépine. |
| DE4107521A1 (de) * | 1991-03-08 | 1992-09-10 | Boehringer Ingelheim Kg | Neue acylaminosubstituierte hetrazepine |
| EP0638560A4 (en) * | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *. |
| EP0937065A1 (en) * | 1996-10-31 | 1999-08-25 | Novo Nordisk A/S | Constrained somatostatin agonists and antagonists |
-
1998
- 1998-06-15 FR FR9807509A patent/FR2779652B1/fr not_active Expired - Fee Related
-
1999
- 1999-06-15 EP EP99925093A patent/EP1087978A1/fr not_active Withdrawn
- 1999-06-15 PL PL99344831A patent/PL344831A1/xx unknown
- 1999-06-15 IL IL13995499A patent/IL139954A0/xx not_active IP Right Cessation
- 1999-06-15 KR KR1020007014166A patent/KR20010052836A/ko not_active Ceased
- 1999-06-15 CA CA002335724A patent/CA2335724A1/fr not_active Abandoned
- 1999-06-15 MY MYPI99002451A patent/MY118652A/en unknown
- 1999-06-15 HU HU0102300A patent/HUP0102300A3/hu unknown
- 1999-06-15 RU RU2001101481/15A patent/RU2229299C2/ru not_active IP Right Cessation
- 1999-06-15 NZ NZ509313A patent/NZ509313A/xx unknown
- 1999-06-15 HK HK02101333.2A patent/HK1039780A1/zh unknown
- 1999-06-15 US US09/701,893 patent/US7015213B1/en not_active Expired - Fee Related
- 1999-06-15 CN CNB998087092A patent/CN100348600C/zh not_active Expired - Fee Related
- 1999-06-15 JP JP2000554742A patent/JP2002518400A/ja active Pending
- 1999-06-15 AR ARP990102861A patent/AR019669A1/es unknown
- 1999-06-15 WO PCT/FR1999/001422 patent/WO1999065917A1/fr not_active Ceased
- 1999-06-15 AU AU41495/99A patent/AU758206B2/en not_active Ceased
- 1999-07-30 TW TW088109993A patent/TW513434B/zh not_active IP Right Cessation
-
2000
- 2000-12-13 NO NO20006352A patent/NO20006352L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1087978A1 (fr) | 2001-04-04 |
| FR2779652A1 (fr) | 1999-12-17 |
| HUP0102300A2 (hu) | 2001-11-28 |
| FR2779652B1 (fr) | 2001-06-08 |
| NO20006352D0 (no) | 2000-12-13 |
| CA2335724A1 (fr) | 1999-12-23 |
| WO1999065917A1 (fr) | 1999-12-23 |
| RU2229299C2 (ru) | 2004-05-27 |
| CN100348600C (zh) | 2007-11-14 |
| US7015213B1 (en) | 2006-03-21 |
| NO20006352L (no) | 2000-12-13 |
| HK1039780A1 (zh) | 2002-05-10 |
| JP2002518400A (ja) | 2002-06-25 |
| KR20010052836A (ko) | 2001-06-25 |
| PL344831A1 (en) | 2001-11-19 |
| CN1309657A (zh) | 2001-08-22 |
| AU4149599A (en) | 2000-01-05 |
| NZ509313A (en) | 2002-11-26 |
| HUP0102300A3 (en) | 2002-10-28 |
| MY118652A (en) | 2004-12-31 |
| AU758206B2 (en) | 2003-03-20 |
| TW513434B (en) | 2002-12-11 |
| IL139954A0 (en) | 2002-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR019669A1 (es) | Uso de diazepinas para la preparacion de medicamentos para el tratamiento de estados patologicos o enfermedades en los cuales esta involucrado por lo menosuno de los receptores de somatostatina, diazepinas utilizadas en dicha preparacion y medicamento y composicion farmaceutica que los contienen. | |
| UY28144A1 (es) | Agentes terapéuticos | |
| UY28150A1 (es) | Agentes terapeuticos | |
| ECSP034642A (es) | Derivados de tetralona como agentes antitumorales | |
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
| EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| DE602004002087D1 (de) | Bis(thio-hydrazid amid) verbindungen zur behandlung von mehrfach resistenten krebs | |
| ECSP045483A (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso | |
| ECSP066405A (es) | Compuestos de aril o heteroaril amida | |
| CY1109498T1 (el) | 18-μεθυλο-19-νορ-17-πρεγν-4-ενο-21,17-καρβολακτονες καθως και φαρμακευτικα σκευασματα που τις περιεχουν | |
| AR054475A1 (es) | Fenilfosfatos sustituidos como profarmacos mutuos de esteroides y (beta)-agonistas para el tratamiento de la inflamacion pulmonar y la broncoconstriccion | |
| MXPA05010824A (es) | Compuestos biciclicos como antagonistas del receptor nr2b. | |
| PA8568101A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso | |
| CR10974A (es) | Inhibidores de carboxipeptidasa b plasmatica (divisional) | |
| DE60001586D1 (de) | Diphenyl-piperidin derivate | |
| ATE57919T1 (de) | Triazinderivate, verfahren zur herstellung der derivate und die derivate als wirksamen bestandteil enthaltende herbizide. | |
| ATE276246T1 (de) | Chemische verbindungen | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| ATE538124T1 (de) | Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit | |
| SE0401763D0 (sv) | Compounds | |
| AR042547A1 (es) | Uso de acidos alfa - feniltiocaboxilico y alfa - feniloxicarboxilico con actividad disminuidora de la glucosa en el suero y de los lipidos en el suero | |
| ATE482955T1 (de) | Azabicyclooctan-3-onderivate und deren verwendung | |
| BR0318533A (pt) | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |